ALCEA ADVISORS welcomes new Senior Advisors to its Leadership Team

ALCEA ADVISORS welcomes new Senior Advisors to its Leadership Team
January 17, 2017 Pedro Marques

ALCEA ADVISORS, the reference partner for oncology startups in Europe, welcomes Dr. Jacques-Pierre Moreau, Dr. Jean Derégnaucourt and Dr. Jean Pierre Armand as Senior Advisors to its Leadership Team

Paris, France, January 17th,  2017 — ALCEA ADVISORS, the reference partner for oncology startups in Europe, announced today the appointment of Dr. Jacques-Pierre Moreau, Dr. Jean Derégnaucourt and Dr. Jean-Pierre Armand as Senior Advisors to its Leadership Team.

Dr. Jacques Pierre Moreau

Dr. Moreau, a renowned and highly respected Executive within the biopharma industry, has more than 30 years of experience in the Health and Life Sciences industry across the spectrum of drug discovery, development and commercialization.

Managing Partner and Cofounder Jean-Sébastien Lénik said “We are proud and honored to welcome Dr. Moreau as part of our Leadership Team. His vision and his exceptional scientific, industry and entrepreneurial track record will be key assets in achieving our objective to revolutionize the cancer patient journey. We are looking forward to partnering with him.”

Dr. Moreau said “ It is with great anticipation that I shall be joining ALCEA’s professional and expert team and contribute to its unique endeavor to provide a solid foundation for early stage companies dedicated to the optimal treatment and supportive care of cancer patients.”

Dr. Jean Derégnaucourt

An Advisor to biotech companies in Europe, Dr. Derégnaucourt has more than 30 years of experience in the Health and Life Sciences industry having served in Senior Executive positions in the public and private sectors.

Managing Partner and Cofounder Jean-Sébastien Lénik said “Dr. Derégnaucourt multifaceted career brings a unique dimension to his contribution at ALCEA ADVISORS. The depth of his experience in industry, with regulators and more recently scouting the most promising startups will be a key enabler to our value proposition. It is a pleasure and honor to have him on board with us.”

Dr. Derégnaucourt said “ALCEA’s novel approach to partnering and investing in oncology is a game changer for the development of the most transformative startups to fight cancer. I am looking forward to joining its talented leadership team and to working with an exceptional pool of experts in the field.”

Dr. Jean-Pierre Armand

Dr. Armand is a distinguished European Oncologist, with more than 40 years of experience in cancer research and clinical oncology, focusing on the identification of novel mechanisms of oncogenesis and early drug development.

Partner and Cofounder Gonçalo Vilaça said : “It is an honor to have Dr. Jean-Pierre Armand on board with us. His pioneering spirit and his unparalleled experience in oncology early drug development globally will bring unique perspectives and guidance to our venture.”

Dr. Armand said “I look forward to contributing to ALCEA’s commitment to early drug development. I am delighted to join forces with a world class leadership team and advisory board to support ALCEA’s focused and dedicated approach to bring innovative treatments to the market and deliver hope for patients.”

About ALCEA ADVISORS

ALCEA ADVISORS (www.alceaadvisors.com) partners and invests in the most transformative European healthcare startups to revolutionize cancer care. We are committed to supporting visionary founders working in the fields of biopharma, medTech, bioinformatics and digital health.

Contact: info@alceaadvisors.com — 72 rue du Faubourg Saint Honoré, 75008 Paris, France.